Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Inhibikase Therapeutics ( (IKT) ) just unveiled an announcement.
On August 14, 2025, Inhibikase Therapeutics announced its financial results for the second quarter of 2025 and highlighted recent advancements. The company is preparing to initiate a Phase 2b clinical study for its lead product candidate, IKT-001, a prodrug of imatinib mesylate, aimed at treating PAH. This follows promising results from previous studies demonstrating the efficacy of imatinib in improving pulmonary vascular resistance and other clinical endpoints. Financially, the company reported a net loss of $9.9 million for the quarter, with increased research and development expenses due to the acquisition of CorHepta and ongoing clinical preparations.
The most recent analyst rating on (IKT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.
Spark’s Take on IKT Stock
According to Spark, TipRanks’ AI Analyst, IKT is a Neutral.
Inhibikase Therapeutics’ stock score is primarily impacted by its poor financial performance, marked by declining revenues and persistent losses. Technical analysis paints a mixed picture, with short-term indicators slightly positive but overshadowed by longer-term negative trends. Valuation metrics indicate caution due to a negative P/E ratio. The recent leadership change provides a potential positive catalyst for future performance, but its impact remains to be seen.
To see Spark’s full report on IKT stock, click here.
More about Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics to modify the course of cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension (PAH). The company specializes in addressing diseases arising from aberrant signaling through the Abelson Tyrosine Kinase and type III receptor tyrosine kinases, including platelet-derived growth factor receptors and c-KIT.
Average Trading Volume: 250,301
Technical Sentiment Signal: Strong Sell
Current Market Cap: $130.1M
See more data about IKT stock on TipRanks’ Stock Analysis page.